NEW YORK, May 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company focused on cell based therapies, announced today that Company management will present at six conferences in June.

International Society for Cellular Therapy Annual Meeting

• Date: June 6, 2012, 6:00 PM PDT
• Venue: Sheraton Seattle, Seattle, WA
• Presenter: Robert A. Preti, Ph.D., President and Chief Scientific Officer of PCT, will give a presentation entitled "On the Entrepreneurial Challenges of Cell Therapy"
  
• Date: June 8, 2012, 1:15 PM PDT
• Venue: Sheraton Seattle, Seattle, WA
• Presenter: Timothy Fong, Ph.D., M.B.A., PCT's Vice President, Technology & Product Development, will give a presentation entitled "From Idea to Product: The Pathway from Academic Innovation to a Commercial Manufacturing Process"

National Investment Banking Association Conference

• Date: June 7, 2012, 10:00 AM EDT
• Venue: Le Parker Meridien Hotel, New York, NY
• Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem

International Society for Stem Cell Research 10th Annual Meeting

• Date: June 15, 2012, 6:00 PM JST
• Venue: Pacifico Yokohama, Yokohama, Japan
• Presenters: Denis Rodgerson, Ph.D., NeoStem's Director of Stem Cell Science, and Aaron M. Havens of University of Michigan will present a poster entitled "First Demonstration That Human Very Small Embryonic-Like (VSEL) Stem Cells Can Regenerate Human Bone In A Model Of Skeletal Repair"

The Biotechnology Industry Organization (BIO) International Conference

• Date: June 19, 2012, 9:15 AM EDT
• Venue: Boston Convention & Exhibition Center, Boston, MA
• Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem

Alliance for Regenerative Medicine – Clinical Outlooks for Regenerative Medicine 2012

• Date: June 19, 2012, 2:45 PM EDT
• Venue: The Starr Center, Schepens Eye Research Institute, Boston, MA
• Presenter: Jonathan Sackner-Bernstein, M.D., F.A.C.C, Vice President of Clinical Development and Regulatory Affairs, will speak on the cardiovascular panel about Amorcyte

Marcum's Inaugural MicroCap Conference

• Date: June 20, 2012
• Venue: The Roosevelt Hotel, New York, NY
• Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, LLC, also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and is enrolling patients in a Phase 2 trial for the preservation of heart function after a heart attack. Amorcyte expects to begin a Phase 1 clinical trial in 2012/2013 for AMR-001 for the treatment of patients with congestive heart failure. Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with its partner Becton-Dickinson. NeoStem's pre-clinical assets include its VSEL™ Technology platform for regenerative medicine, which NeoStem believes to be an endogenous, pluripotent, non-embryonic stem cell that has the potential to change the paradigm of cell therapy as we know it today.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's successful development of cell therapeutics, as well as the future of the cell therapeutics industry. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Trout Group
         Gitanjali Jain Ogawa, Vice President
         Phone: +1-646-378-2949
         Email: gogawa@troutgroup.com
         
         NeoStem, Inc.
         Robin Smith, CEO
         Phone: +1-212-584-4174
         Email: rsmith@neostem.com